Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. Beaker In a May 20 research report, ROTH Capital Partners analyst Yasmeen Rahimi reported that The Medicines Company's (MDCO:...
Streetwise Reports | May 30, 2019 |

Bacteria Test Developer Reiterates Revenue Should Double in 2019

The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. In a May 31 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. lowered its target price on T2 BioSystems Inc. (TTOO:NASDAQ) to $10 per sha...
Streetwise Reports | June 10, 2019 |

U.S. spot Bitcoin ETFs are live – what happens to Canada’s crypto ETFs?

By Shaed Hashimkhial The SEC’s endorsement of U.S. spot Bitcoin ETFs significantly influenced the cryptocurrency markets. Shortly after the announcement, we witnessed a substantial rally in Bitcoin, a notable increase in Ethereum’s...
Research | March 26, 2024 |

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its e...
Streetwise Reports | March 25, 2019 |

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...
Streetwise Reports | September 5, 2019 |

Metals React To Fed Shockwaves – Ready For Next Move

On July 31, 2019, the US Federal Reserve decreased the Federal Funds Rate (FFR) by 25 basis points. We believe the US Fed was pushed to take this action for three reasons that are directly related to the fear and greed that is abundant in the global markets. Reason #1 Fed H...
Chris Vermeulen | August 1, 2019 |

Multi-billion dollar valuation set for dynaCERT Inc. (V.DYA), pieces falling into place

dynaCERT Inc. (TSX VENTURE: DYA) (OTCQB: DYFSF) (FRA: DMJ) this week announced it has received its European ABE (German for “permit of operation”) certification for the Company’s HydraGEN™ (HG) Carbon Emission Reduction Technology fo...
James O'Rourke | August 27, 2019 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Exclusive CEO Interview, Sam Spring of Kincora Copper

Kincora Copper [TSX-V: KCC] fell off investor’s radar screens due to an extended period of inactivity in 2018, but now the Company is cashed up, team in place, and ready for extensive drilling at 5 independent, large-scale porphyry targets with a 12-month funded budget for u...
Peter Epstein | June 27, 2019 |

Not only balloons: Use-cases and key players in global helium market

Whether you’re seeking exposure to exploration upside or established profitability, the helium market offers compelling candidates for the commodity sleeve of your portfolio. Helium is an essential resource notable for its widespread use-cases and p...
Trevor Abes | September 5, 2024 |
1 2 3 4 5 6 7 8 9 10 ...